Revolutionizing Gastric Cancer Detection: Introducing Cizzle Bio’s New Blood Test
At Cizzle Bio, we are committed to transforming the way cancer is detected and treated. We are thrilled to announce the development of our latest innovation: a non-invasive blood test for the early detection of gastric cancer. This test represents another step forward in our mission to detect cancer early and save lives.
The Challenge of Gastric Cancer Detection
Gastric cancer is one of the most lethal cancers globally, often diagnosed at advanced stages when treatment options are limited. Here are the challenges we aim to address:
Late Detection: Gastric cancer symptoms often mimic common gastrointestinal issues, leading to delays in diagnosis.
High Mortality: As the second most lethal cancer worldwide, early detection is critical to improving survival rates.
Invasive Procedures: Current diagnostic methods like endoscopy are invasive, resource-intensive, and often not accessible to all patients.
These challenges highlight the urgent need for innovative solutions that prioritize early detection.
About the New Gastric Cancer Blood Test
Our new test, DEX-G2, is designed to detect gastric cancer in its earliest stages using a simple blood sample. This groundbreaking technology combines the power of two key biomarker systems to achieve unmatched accuracy:
Dual Approach: DEX-G2 uses both cell-free miRNAs, which signal changes in the body, and exosomal miRNAs, which are specific to tumor origins. This innovative combination enhances sensitivity and specificity.
High Accuracy: Clinical studies have demonstrated:
Sensitivity (early-stage detection): 95%
Specificity (early-stage detection): 97%
Non-Invasive: Unlike traditional endoscopy, DEX-G2 only requires a simple blood draw, making it more accessible and less burdensome for patients.
How DEX-G2 Can Make a Difference
For Patients
Reduces the need for invasive diagnostic procedures.
Identifies cancer at earlier stages, improving survival rates and expanding treatment options.
For Clinicians
Enhances diagnostic precision, offering a reliable tool for identifying early-stage gastric cancer.
Integrates easily into existing workflows, providing faster and more actionable results.
For Healthcare Systems
Cost-effective and scalable, making it an ideal solution for widespread screening in high-risk populations.
The Science Behind the Test
The development of DEX-G2 was inspired by the groundbreaking work of Dr. Ajay Goel, a leader in miRNA and exosomal biomarker research. His innovative hypothesis—combining cell-free and exosomal miRNAs—created a new standard in precision diagnostics.
Extensive multi-center studies involving nearly 1,000 patients validated the test’s effectiveness across diverse populations. These studies confirm that tumor-released exosomes in the blood can serve as a “liquid biopsy,” providing direct tumor-derived markers for accurate detection.
Aligning with Cizzle Bio’s Mission
Our mission, “Detect Early, Save Lives,” drives everything we do at Cizzle Bio. With DEX-G2, we are expanding our focus beyond lung cancer to address another life-threatening disease. Together, our tests showcase our commitment to leading the field of biomarker-based cancer diagnostics.
What’s Next?
While we are finalizing the launch plans for the DEX-G2 test, we are already seeing the potential impact it can have in transforming gastric cancer detection. A full product launch is planned for early 2025, where we will share more details about its availability and application.
Stay Informed
To learn more about our groundbreaking innovations and stay updated on the latest developments, visit our Gastric Cancer Test page or sign up for our newsletter.
With DEX-G2, Cizzle Bio continues to pave the way for early cancer detection, ensuring that patients and clinicians have the tools they need to fight cancer effectively.
Together, let’s move toward a future where cancer is caught early and lives are saved.
